Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 1

Status

Unknown 5Completed 1

Sponsor Class

OTHER 224INDUSTRY 48OTHER_GOV 11UNKNOWN 6

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 3Head & Neck 2Thoracic 1

Conditions

Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Nasopharyngeal Carcinoma 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 20Capecitabine 18S 1 (combination) 17Cisplatin 15Oxaliplatin 11Radiotherapy, Intensity-Modulated 9apatinib 8Epirubicin 8Docetaxel 8Carboplatin 8Radiotherapy 7Irinotecan 7titanium silicide 6sintilimab 6pyrotinib 6nimotuzumab 6anlotinib 6Drug Therapy 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6nedaplatin 5camrelizumab 5Temozolomide 5Etoposide 5Bevacizumab 5nabiximols 4Vinorelbine 4Trastuzumab 4Radiation Dose Hypofractionation 4Radiation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
UNKNOWN × anlotinib × Clear all
NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

ChineseAMS

Phase 2 Unknown
35 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04999800 2021-08-11

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

ChineseAMS

Phase 2 Unknown
20 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04452370 2021-07-21

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

ChineseAMS

Phase 2 Unknown
100 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04620837 2020-11-09

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

ChineseAMS

Phase 2 Unknown
25 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

ChineseAMS

Phase 2 Completed
26 enrolled
Breast

Breast Neoplasms

NCT03639467 2018-09-18

Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

ChineseAMS

Phase 1/2 Unknown
40 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡